|
KR102764250B1
(ko)
|
2015-09-14 |
2025-02-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
|
CA3049980A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
|
CA3059348A1
(en)
|
2017-04-11 |
2018-10-18 |
Regeneron Pharmaceuticals, Inc. |
Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
|
|
KR102712142B1
(ko)
|
2017-07-31 |
2024-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
|
WO2019067875A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
|
|
AU2018348195B2
(en)
|
2017-10-11 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
MY207352A
(en)
|
2018-03-21 |
2025-02-21 |
Regeneron Pharma |
17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
GB2606038B
(en)
|
2018-09-04 |
2023-05-03 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
GB2600800B
(en)
*
|
2018-09-04 |
2023-08-16 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス,インコーポレーテッド |
第ix因子を発現するための組成物及び方法
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
CN113939595A
(zh)
|
2019-06-07 |
2022-01-14 |
瑞泽恩制药公司 |
包括人源化白蛋白基因座的非人动物
|
|
KR20220024053A
(ko)
|
2019-06-14 |
2022-03-03 |
리제너론 파마슈티칼스 인코포레이티드 |
타우병증의 모델
|
|
KR20220044816A
(ko)
*
|
2019-08-12 |
2022-04-11 |
인티그레이티드 나노테라퓨틱스 아이엔씨. |
하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
CN111467321A
(zh)
*
|
2020-03-26 |
2020-07-31 |
深圳市新合生物医疗科技有限公司 |
一种mRNA核酸类药物胞内递送系统、制备方法和应用
|
|
US20240293317A1
(en)
*
|
2020-04-20 |
2024-09-05 |
Board Of Regents, The University Of Texas System |
Lipid nanoparticle (lnp) delivery systems and uses thereof
|
|
GB202008821D0
(en)
*
|
2020-06-10 |
2020-07-22 |
Highersteaks Ltd |
Systems and methods for cell conversion
|
|
MX2023000511A
(es)
*
|
2020-07-10 |
2023-02-13 |
Genevant Sciences Gmbh |
Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
MX2023011227A
(es)
|
2021-03-22 |
2023-12-06 |
Recode Therapeutics Inc |
Composiciones y metodos para administracion dirigida a celulas.
|
|
MX2023011243A
(es)
|
2021-03-23 |
2023-12-14 |
Recode Therapeutics Inc |
Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
|
|
WO2022212838A1
(en)
*
|
2021-04-02 |
2022-10-06 |
Tiba Biotech Llc |
Dendritic architectures as nonviral vectors in gene delivery
|
|
IL307526A
(en)
*
|
2021-04-13 |
2023-12-01 |
Westgene Biopharma Co Ltd |
Ionizable lipids and preparations for the transport of nucleic acids
|
|
CN113637708B
(zh)
*
|
2021-08-09 |
2023-07-25 |
中国科学院过程工程研究所 |
一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
AU2022408167A1
(en)
|
2021-12-08 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
US20260151350A1
(en)
*
|
2021-12-27 |
2026-06-04 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeted delivery to cells
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US12011507B2
(en)
|
2022-04-01 |
2024-06-18 |
Nanovation Therapeutics Inc. |
MRNA delivery composition
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2024086929A1
(en)
*
|
2022-10-25 |
2024-05-02 |
Nanovation Therapeutics Inc. |
Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
|
|
WO2024112775A1
(en)
*
|
2022-11-25 |
2024-05-30 |
Beam Therapeutics Inc. |
Compositions and methods for editing a transthyretin gene
|
|
IL321026A
(en)
|
2022-12-08 |
2025-07-01 |
Recode Therapeutics Inc |
Nanoparticle formulations and their uses
|
|
CN119343153A
(zh)
*
|
2022-12-27 |
2025-01-21 |
北京炫景瑞医药科技有限公司 |
一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
|
|
CN118946544A
(zh)
*
|
2023-03-09 |
2024-11-12 |
上海吉量医药工程有限公司 |
可离子化脂质分子及其制备方法和应用
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
CN116271105B
(zh)
*
|
2023-05-18 |
2023-08-25 |
上海贝斯昂科生物科技有限公司 |
一种适于rpe细胞转染的脂质纳米颗粒及其应用
|
|
EP4719352A1
(en)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
US12599560B2
(en)
|
2023-11-02 |
2026-04-14 |
Longuide Biopharma Corporation |
Lipids and lipid nanoparticle formulations
|
|
WO2025091377A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Longuide Biopharma Corporation |
Lipids and lipid nanoparticle formulations
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2026122685A1
(en)
|
2024-12-03 |
2026-06-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2026165530A1
(en)
|
2025-02-03 |
2026-08-06 |
Renagade Therapeutics Management Inc. |
Hydrophilic polymer lipids for use in lipid nanoparticles
|